The anti-HER2 antibody trastuzumab is used for the treatment of HER2-overexpressing breast cancer patients and the EGFR/ HER2 kinase inhibitor lapatinib is used for the treatment of HER2-overexpressing metastatic breast cancer patients who have progressed on trastuzumab therapy. The gene discussed is ERBB2; the disease is breast cancer.